Skip to content
Non-Current Liabilities

Debt Maturity - 2027

Merck & Co. Debt Maturity - 2027 increased by 58.8% to $2.7B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 58.8%, from $1.7B to $2.7B. Over 5 years (FY 2020 to FY 2025), Debt Maturity - 2027 shows relatively stable performance with a 1.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryRisk
SignalLower is better
VolatilityStable
First reportedQ4 2015
Last reportedQ4 2025Feb 24, 2026

How to read this metric

Higher maturity amounts indicate a greater need for future cash flow or access to capital markets for refinancing.

Detailed definition

This represents the total principal amount of long-term debt scheduled to mature during the calendar year 2027. It provi...

Peer comparison

Standard debt maturity profile disclosure found in the notes to financial statements for public companies.

Metric ID: debt_maturity_2027

Historical Data

5 periods
 Q4 '21Q4 '22Q4 '23Q4 '24Q4 '25
Value$2.3B$1.5B$2.1B$1.7B$2.7B
QoQ Change-34.8%+40.0%-19.0%+58.8%
YoY Change-34.8%+40.0%-19.0%+58.8%
Range$1.5B$2.7B
CAGR+17.4%
Avg YoY Growth+11.2%
Median YoY Growth+10.5%

Frequently Asked Questions

What is Merck & Co.'s debt maturity - 2027?
Merck & Co. (MRK) reported debt maturity - 2027 of $2.7B in Q4 2025.
How has Merck & Co.'s debt maturity - 2027 changed year-over-year?
Merck & Co.'s debt maturity - 2027 increased by 58.8% year-over-year, from $1.7B to $2.7B.
What is the long-term trend for Merck & Co.'s debt maturity - 2027?
Over 5 years (2020 to 2025), Merck & Co.'s debt maturity - 2027 has grown at a 1.6% compound annual growth rate (CAGR), from $2.5B to $2.7B.
What does debt maturity - 2027 mean?
The total debt principal coming due for repayment in 2027.